Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

NCT04588480 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection
COVID-19

Interventions

BIOLOGICAL: BNT162b2
OTHER: Placebo

Sponsor

BioNTech SE

Collaborators

[object Object]